1. Home
  2. COMP vs ACAD Comparison

COMP vs ACAD Comparison

Compare COMP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Inc.

COMP

Compass Inc.

HOLD

Current Price

$10.33

Market Cap

4.9B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.28

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COMP
ACAD
Founded
2012
1993
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.6B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
COMP
ACAD
Price
$10.33
$27.28
Analyst Decision
Strong Buy
Buy
Analyst Count
9
21
Target Price
$10.39
$29.24
AVG Volume (30 Days)
12.7M
1.5M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
N/A
1.54
Revenue
$6,642,200,000.00
$1,047,118,000.00
Revenue This Year
$25.14
$15.16
Revenue Next Year
$12.29
$11.42
P/E Ratio
N/A
$17.80
Revenue Growth
24.27
12.69
52 Week Low
$5.10
$13.40
52 Week High
$11.03
$27.61

Technical Indicators

Market Signals
Indicator
COMP
ACAD
Relative Strength Index (RSI) 67.68 76.30
Support Level $10.32 $22.81
Resistance Level $10.94 $25.20
Average True Range (ATR) 0.41 0.86
MACD 0.00 0.31
Stochastic Oscillator 63.09 96.35

Price Performance

Historical Comparison
COMP
ACAD

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: